Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Michigan researchers use Raman spectroscopy to study various childhood diseases

Renishaw, a world leader in metrology and spectroscopy, reports on the use of its inVia confocal Raman microscope in the study of various diseases–with a major focus on childhood diseases–at the Children's Hospital of Michigan and Wayne State University.

6 Oct 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

The National Institutes of Health has awarded $346,000 to Worcester Polytechnic Institute for a three-year research project to advance development of a chemical process that could significantly improve the ability to design new pharmaceuticals and streamline the manufacturing of existing drugs.

24 Sep 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

The American Gastroenterological Association, in partnership with the Crohn's & Colitis Foundation of America and Janssen Biotech, Inc., announced today that Theresa Alenghat, VMD, PhD, from Cincinnati Children's Hospital Medical Center, OH, was awarded with the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research.

27 Aug 2015

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.

26 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics, Inc. announces the launch of an observational clinical study in patients who contracted Progressive Multifocal Leukoencephalopathy (PML), the rare and often fatal brain infection that arises as an unintended side effect of some medications used for treatment of Multiple Sclerosis, Crohn's disease, Ulcerative Colitis and certain cancers of the blood and lymph.

13 Aug 2015

Adults exposed to childhood physical or sexual abuse at risk for ulcerative colitis

Adults who were exposed to childhood physical or sexual abuse were approximately twice as likely to have ulcerative colitis, according to a new nationally representative study from four researchers at the University of Toronto.

7 Aug 2015

Study uncovers role of intra-abdominal fat cells in development and progression of IBD

Intra-abdominal fat cells may contribute to the development and progression of inflammatory bowel disease (IBD), according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

6 Aug 2015

People with IBD experience higher anxiety risk compared to peers without IBD

People who have inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, have twice the odds of having a generalized anxiety disorder at some point in their lives when compared to peers without IBD, according to a new study published by University of Toronto researchers.

30 Jul 2015

Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno, a unique trans-galactooligosaccharide, and the Department of Food and Nutritional Sciences, The University of Reading, UK, today announce the results of human research demonstrating the positive effects of an advanced prebiotic on the immune system of the elderly.

29 Jul 2015

Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Twenty young and promising researchers from Nijmegen - eleven from Radboud University and nine from Radboudumc - are each to receive up to 250,000. NWO (The Netherlands Organisation for Scientific Research) is awarding the Veni grant as part of the Innovational Research Incentives Scheme.

25 Jul 2015

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information.

24 Jul 2015

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania.

22 Jul 2015

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

14 Jul 2015

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca.

9 Jul 2015

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

A technology whose roots date to the 1800s has the potential to offer an extraordinary new advantage to modern-day medicine.

9 Jul 2015

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.

8 Jul 2015

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Michigan researchers use Raman spectroscopy to study various childhood diseases

Common IBD therapeutic target may protect against intestinal inflammation

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

Immune Pharmaceuticals’ CEO establishes stock trading plan

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Adults exposed to childhood physical or sexual abuse at risk for ulcerative colitis

Study uncovers role of intra-abdominal fat cells in development and progression of IBD

People with IBD experience higher anxiety risk compared to peers without IBD

Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Study shows regions of genome underlying IBD consistent around the world

Biosimilars show promise for children with IBD, but more research needed

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in